bluebird bio Inc BLUE:NASDAQ

Last Price$6.70Cboe Real-Time Last Sale as of 9:36AM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.12(1.82%)
Bid (Size)$6.67 (200)
Ask (Size)$6.69 (205)
Day Low / High$6.29 - 6.71
Volume128.9 K
 

View Biotechnology IndustryPeer Comparison as of 08/17/2022

 

bluebird bio Inc ( NASDAQ )

Price: $6.70
Change: +0.12 (1.82%)
Volume: 128.9 K
9:36AM ET 8/17/2022
 
 

Scholar Rock Holding Corp ( NASDAQ )

Price: $9.70
Change: -0.02 (0.21%)
Volume: 210.00
9:33AM ET 8/17/2022
 
 

Precigen Inc ( NASDAQ )

Price: $2.42
Change: +0.01 (0.41%)
Volume: 24.00
9:35AM ET 8/17/2022
 
 

Vaxart Inc ( NASDAQ )

Price: $4.18
Change: +0.02 (0.60%)
Volume: 8.9 K
9:36AM ET 8/17/2022
 
 

MiMedx Group Inc ( NASDAQ )

Price: $4.21
Change: -0.01 (0.24%)
Volume: 23.00
9:33AM ET 8/17/2022
 

Read more news Recent News

--Barclays Lifts bluebird bio to Equalweight From Underweight, Price Target to $5 From $3
4:45AM ET 8/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--RBC Cuts Price Target on bluebird bio to $10 From $14, Maintains Sector Perform-Speculative Risk Rating
8:22AM ET 8/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (BLUE) BLUEBIRD BIO Reports Q2 Revenue $1.5M
4:26PM ET 8/04/2022 MT Newswires

...

--Raymond James Upgrades bluebird bio to Outperform From Market Perform; Price Target is $8
5:34AM ET 8/02/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business Descriptionbluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA. View company web site for more details
Address455 Grand Union Boulevard
Somerville, Massachusetts 02145
Phone+1.339.499.9300
Number of Employees764
Recent SEC Filing08/08/20224
President, Chief Executive Officer & DirectorAndrew Obenshain
Chief Operating & Commercial OfficerThomas J. Klima
Chief Financial, Accounting & Strategy OfficerJason F. Cole
Chief Medical OfficerRichard Colvin

Company Highlights

Price Open$6.76
Previous Close$6.58
52 Week Range$2.87 - 25.39
Market Capitalization$516.7 M
Shares Outstanding77.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$8.61
Beta vs. S&P 500N/A
Revenue$54.6 M
Net Profit Margin-2,059.44%
Return on Equity-135.40%

Analyst Ratings as of 08/05/2022

Buy
0
Overweight
1
Hold
8
Underweight
0
Sell
2
Consensus RecommendationConsensus Icon
Powered by Factset